Agenus Inc (AGEN) Stock Price, Quote & News

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 674 4400

Fax: 781 674 4200

Website: www.agenusbio.com

Address:

3 Forbes Road, Lexington, United States

robbiekuss1 Sep. 14 at 9:53 PM

$AGEN @BakerBrother @kevintcryder So Baker & Kevin, if you had to guess at what AGEN will project to the medical community in October what will it be? Just curious.

1 · Reply

BakerBrother Sep. 14 at 7:58 PM

To keep things organized for myself, I compiled a list of the $AGEN trials in descending order from trial start date. By my count, excluding the compassionate use access trial 25 Agenus + ISTs sponsored trials. I included C-800-01 on the list even though it's not ongoing since we will be hearing about OS at ESMO Oct 17-21. Takeaway: Agenus has said that they have dosed 1,200 patients. The C-800-25 (Metastatic CRC), C-800-23 (Melanoma) and C-800-22 (PDAC) account for 489 patients and based on the day count elapsed since trial start (between 922 - 1,019 days) that we should expect OS data from these key trials soon. I have also highlighted in green all the trials that have been active for over 2 years (9 out of 25 trials). Of these trials, I am most interested in the neoadjuvant NEST and UNICORN trials. Also, the neoadjuvant NEOASIS which has been ongoing for 594 days.

5 · Reply

2_logs_higher Sep. 14 at 3:22 PM

$AGEN A plea to Agenus management and BOD. Please realign the priorities of Agenus as follows: 1. Consummate the Zydus deal rather than daily ATM! 2. Consummate a MOAD 3. Focus on Cancer patients 4. Get BOT-BAL CRC approved 5. Address shareholders concerns 6. After 1-5 the money will easily flow to charities - schools more so than currently. Agenus shareholders don't even seem to be on the priority list. New school 9/12/2025.

2 · Reply

2_logs_higher Sep. 14 at 3:10 PM

$AGEN Agenus needs political intervention to slow down competition from over taking Agenus lead, but along the way Agenus needs to stop making poor decisions. Do a MOAD with a large US BP, not soon , but very soon! https://www.biospace.com/policy/trump-reportedly-preparing-order-restricting-chinese-drug-licensing-deals Even Grok agrees with me.

0 · Reply

BakerBrother Sep. 14 at 2:21 PM

$AGEN Does anyone know what trial this oral presentation will be drawing upon for the upcoming ESMO Oct 17-21? I'm thinking it's this one: NCT03860272 https://clinicaltrials.gov/study/NCT03860272?term=C-800-01&rank=1 Presentation Details: 1. Oral Presentation Title:Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors Presenting Author: Dr. Michael Gordon; HonorHealth Research Institute-AZ, USA Mini Oral Session: Investigational Immunotherapy Session Date: Friday, October 17, 2025 Session Time: 2:00-3:00 PM CEST / 8:00-9:30 AM EDT Location: Hall 5.2 Abstract Number: 3220 https://investor.agenusbio.com/news/news-details/2025/Agenus-to-Highlight-Emerging-Survival-Plateaus-with-BotensilimabBalstilimab-in-Oral-Presentation-of-Study-in-Refractory-Patients-Across-Five-Tumor-Types-at-ESMO-2025/default.aspx

1 · Reply

gooy5 Sep. 14 at 12:46 PM

$AGEN https://www.theglobeandmail.com/investing/markets/stocks/AGEN-Q/pressreleases/34688434/france-grants-reimbursed-compassionate-access-aac-for-agenus-bot-bal-in-refractory-mss-metastatic-colorectal-cancer/

0 · Reply

joechuck71 Sep. 14 at 1:08 AM

$AGEN i think this says it all "AI Overview As of late 2025, one of the most promising non-chemotherapy, non-approved drugs for metastatic colorectal cancer (mCRC) is botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody. Still in clinical trials, this immunotherapy is showing encouraging results, especially for the large patient population with microsatellite stable (MSS) mCRC that does not typically respond to immunotherapy. "

1 · Reply

BillyBobBleach Sep. 13 at 9:44 PM

$AGEN France AAC > US compassionate use https://oncodaily.com/voices/jennifer-buell-367914

1 · Reply

dugger Sep. 13 at 2:01 PM

$AGEN i wonder who paid for Garo's expenses etc. on his most recent ( Sept 1) trip to Armenia for his charity, at a time AGEN shareholders need him to concentrate on securing funding. Seems he's more interested in "his charity". Interesting that Armenia does not have an extradition treaty with the U, S.

2 · Reply

2_logs_higher Sep. 13 at 12:28 PM

$AGEN Zydus continues to expand - we just need Zydus to sign on the bottom line and transfer the check! Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market. The total addressable market opportunity of Ozanimod Capsules in the U.S is approximately US $637 million as per the IQVIA MAT July 2025. https://finance.yahoo.com/news/zydus-synthon-entered-exclusive-licensing-122800706.html

0 · Reply

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 5, 2025, 8:52 AM EDT - 9 days ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 2:04 PM EDT - 17 days ago

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Aug 26, 2025, 9:37 AM EDT - 19 days ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 19, 2025, 7:30 AM EDT - 26 days ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 11, 2025, 7:30 AM EDT - 4 weeks ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Jul 31, 2025, 7:30 AM EDT - 6 weeks ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

$Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025$

Jul 25, 2025, 12:46 PM EDT - 7 weeks ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

$Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3$

Jul 7, 2025, 8:55 AM EDT - 2 months ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jun 17, 2025, 7:30 AM EDT - 3 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 10, 2025, 1:30 PM EDT - 3 months ago

Agenus Announces Virtual Annual Shareholders Meeting

Jun 4, 2025, 2:38 PM EDT - 3 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 3, 2025, 7:00 AM EDT - 3 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

May 30, 2025, 7:30 AM EDT - 3 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 23, 2025, 3:09 PM EDT - 4 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 15, 2025, 10:40 AM EDT - 4 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 12, 2025, 2:46 PM EDT - 4 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:30 AM EDT - 4 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:20 AM EDT - 4 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Apr 29, 2025, 7:30 AM EDT - 4 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 28, 2025, 3:30 PM EDT - 4 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 25, 2025, 1:05 PM EDT - 5 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 23, 2025, 12:05 PM EDT - 5 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Mar 25, 2025, 4:40 PM EDT - 6 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 19, 2025, 7:30 AM EDT - 6 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 11, 2025, 10:39 AM EDT - 6 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 6 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Feb 26, 2025, 4:48 PM EST - 7 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 25, 2025, 2:30 PM EST - 7 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 8:26 AM EST - 7 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:33 AM EST - 7 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 7 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 7 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

$Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas$

Jan 29, 2025, 12:37 PM EST - 8 months ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 22, 2025, 2:48 PM EST - 8 months ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Dec 18, 2024, 7:30 AM EST - 9 months ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 5, 2024, 7:30 AM EST - 10 months ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Nov 27, 2024, 8:15 AM EST - 10 months ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 12, 2024, 10:41 AM EST - 10 months ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 10 months ago

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Nov 7, 2024, 10:00 AM EST - 11 months ago

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Nov 5, 2024, 7:30 AM EST - 11 months ago

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Nov 4, 2024, 11:00 AM EST - 11 months ago

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 11 months ago

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

robbiekuss1 Sep. 14 at 9:53 PM

$AGEN @BakerBrother @kevintcryder So Baker & Kevin, if you had to guess at what AGEN will project to the medical community in October what will it be? Just curious.

1 · Reply

BakerBrother Sep. 14 at 7:58 PM

5 · Reply

2_logs_higher Sep. 14 at 3:22 PM

2 · Reply

2_logs_higher Sep. 14 at 3:10 PM

0 · Reply

BakerBrother Sep. 14 at 2:21 PM

1 · Reply

gooy5 Sep. 14 at 12:46 PM

0 · Reply

joechuck71 Sep. 14 at 1:08 AM

1 · Reply

BillyBobBleach Sep. 13 at 9:44 PM

$AGEN France AAC > US compassionate use https://oncodaily.com/voices/jennifer-buell-367914

1 · Reply

dugger Sep. 13 at 2:01 PM

2 · Reply

2_logs_higher Sep. 13 at 12:28 PM

0 · Reply

MoneyGroupLLC Sep. 13 at 10:11 AM

Enter: $AGEN OCT 17 2025 $5 CALLS Buy in Price: $0.45 - $0.45 Take Profit: $0.55 Stop Bleeding: $0.40 ROI Potential: 22% Exit Within: 39 Minutes https://moneygroup.us/alerts

0 · Reply

joechuck71 Sep. 13 at 1:06 AM

$AGEN Additionally, Agenus’s ongoing efforts to expand clinical evidence and explore further applications of their treatments across various tumor types further solidify the company’s growth prospects and justify the Buy rating

0 · Reply

joechuck71 Sep. 13 at 1:06 AM

$AGEN $23 Emily Bodnar has given her Buy rating due to a combination of factors that highlight Agenus’s promising developments and strategic positioning in the oncology market. One of the key reasons is the recent authorization of botensilimab and balstilimab for compassionate use in France for patients with refractory microsatellite-stable metastatic colorectal cancer. This approval not only provides an additional revenue stream for Agenus but also helps in gathering real-world clinical evidence, which is crucial for supporting the broader use of these treatments. Furthermore, the Phase 1 trial results for botensilimab and balstilimab in this patient population have shown encouraging survival rates and durable tumor responses, indicating a potential breakthrough for patients resistant to existing immunotherapies. The significant unmet need in colorectal cancer, particularly in France, underscores the importance of these developments.

3 · Reply

Moon37 Sep. 12 at 10:53 PM

$SPY $AGEN

0 · Reply

Garo_is_a_Con_Man Sep. 12 at 10:27 PM

$AGEN Don't Trust Garo the Con Man or any of the Pumpers.

0 · Reply

Biotechguy21 Sep. 12 at 9:06 PM

$AGEN are you surprised by this?

0 · Reply

Night_Owl_Biotech Sep. 12 at 8:58 PM

Attached is a table showing the changes in share price for the week ending today for all 34 commercial-stage oncology focused bios with market caps north of $100MM. There were 3 healthcare investor conferences this week & Wells Fargo was last week. 2/3's of bios in this peer group were down while the $XBI was off 1.4% $AGEN technically joined this peer group this week after France approved AGEN's Bot/Bal combo therapy for emergency use & hence will reimburse at cost. Bot/Bal produced its first complete response ~5 years ago followed by a 2nd CR a few months later. Bot/Bal has been tested in over 1,000 patients & yet is still unavailable for commercial-use in the United States. We have no idea if characterizing AGEN as commercial-stage is appropriate. Genuine feedback/pushback would be appreciated (without bashing mgmt). $IBRX was the best performing stock in the peer group this week $NUVB $VSTM both saw meaningful declines after healthy run ups last week.

6 · Reply

Moon37 Sep. 12 at 8:02 PM

$AGEN God grant me the Serenity to accept the things I cannot change, Courage to change the things i can, and the Wisdom to know the difference

0 · Reply

2_logs_higher Sep. 12 at 8:00 PM

$AGEN Where's G. O, he is off in Armenia opening schools while Agenus drips, drips drips. I guess there are no term sheets to review for the next week or so, unless he adopts the Biden auto pen.

1 · Reply

Moon37 Sep. 12 at 7:39 PM

$AGEN 37>21 https://youtu.be/HHnCWWO-fXg?si=MpUdsCL2ocgSEq_3

0 · Reply

Moon37 Sep. 12 at 7:22 PM

$AGEN https://youtu.be/iX6a3AFmr-c?si=NfrF7uLSPqmE_is3

0 · Reply

2_logs_higher Sep. 12 at 7:21 PM

$AGEN The BOT/BAL Breakthrough: A New Era for Colorectal Cancer Treatment https://www.targetedonc.com/view/the-bot-bal-breakthrough-a-new-era-for-colorectal-cancer-treatment

0 · Reply

Market Cap	142.75M
Revenue (ttm)	103.46M
Net Income (ttm)	-227.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	7.83
Profit Margin	-219.61%
Debt to Equity Ratio	-0.10

Volume	354,700
Avg Vol	822,978
Day's Range	N/A - N/A
Shares Out	31.86M
Stochastic %K	34%
Beta	1.44
Analysts	Sell
Price Target	$12.33